Background and aims: Mucosal healing in ulcerative colitis (UC) has become a common endpoint in most clinical trials and a relevant therapeutic goal in clinical practice. Despite important differences between endoscopic Mayo scores 0 and 1, both scores are considered as mucosal healing in most important trials. The aim of the present study was to evaluate the risk of relapse in UC patients according to the degree of mucosal healing (endoscopic Mayo scores of 0 and 1). Methods: A prospective longitudinal cohort study was designed. All UC patients who presented with mucosal healing at colonoscopy were consecutively included. Mucosal healing was defined as an endoscopic Mayo score of 0 or 1. Clinical relapse was defined as the need for therapy to induce remission, any treatment escalation, hospitalization or colectomy. All clinical relapses were evaluated at months 6 and 12 after study entry. Results were subjected to unconditional stepwise logistic and Kaplan-Meier regression analysis. Results: One hundred and eighty-seven consecutive UC patients (126 [67.3%] with Mayo score 0 and 61 [32.7%] with Mayo score 1) were included. Of patients with Mayo scores 0 and 1, 9.4 and 36.6% respectively presented a relapse during the first 6 months of follow-up (p < 0.001). The only factor independently associated with UC relapses in the multivariate analysis was an endoscopic Mayo score of 1 (odds ratio 6.27, 95% confidence interval 2.73-14.40, p < 0.001).
Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by periods of remission and exacerbation. Patients, especially those with extensive disease, undergo several colonoscopies during their clinical course, not only to assess the activity of the disease, but also to detect premalignant lesions. 1 Since UC is limited to the mucosa, mucosal healing represents an important therapeutic goal. Mucosal healing is associated with a better prognosis of UC by reducing relapses, 2 reducing colectomy rates 3 and improving quality of life of patients.
features. 5 Recent clinical trials have used the endoscopic Mayo Score, 6 which is easy to apply to clinical trials and clinical practice. The endoscopic Mayo score has, however, some weaknesses, such as the lack of a validated definition of mucosal healing and the inclusion of the subjective term of minimal or slight friability, which could lead to inconsistent results. 7 Mucosal healing is defined as an endoscopic Mayo score of 0 or 1 in most relevant clinical trials. Defined in this way, mucosal healing is consistently more frequently achieved than clinical remission in clinical trials regardless of the investigated drug (infliximab, adalimumab or golimumab) and the aim (induction or maintenance) of the study. [8] [9] [10] We hypothesized that mucosal healing should be defined just as an endoscopic Mayo score of 0. The aim of the present study was to evaluate the risk of relapse in UC patients according to the endoscopic Mayo score used to define mucosal healing.
Methods
A prospective longitudinal cohort study was designed and performed at the IBD Unit of the Department of Gastroenterology of the University Hospital of Santiago de Compostela, Spain. Adult UC patients (≥18 years old) in clinical remission (defined as a partial Mayo score ≤2) for at least 3 months and who were scheduled for surveillance colonoscopy were considered for inclusion in the study. Signed informed consent was obtained after explanation of the study aims and design, which had been previously approved by the local ethics committee. Patients underwent a colonoscopy between January 2011 and July 2012 and those presenting mucosal healing (endoscopic Mayo score of 0 or 1) were finally included. An incomplete colonoscopy and any previous colon resection or pouch were considered as exclusion criteria.
Demographic features, medical history, toxic habits and therapy for UC (including topical treatment and combinations of more than one drug) were recorded at entry. Clinical remission was confirmed by a partial Mayo score ≤2 at the time of colonoscopy. After colonoscopy, the extent of the disease according to the Montreal classification (E1, ulcerative proctitis; E2, left-sided UC; E3, extensive colitis) was recorded. In addition, the endoscopic Mayo score was evaluated. Mayo score 0 was defined as the presence of a normal mucosa or inactive disease. Mayo score 1 was defined as the presence of erythema, decreased vascular pattern or mild friability. If endoscopic Mayo scores varied among different colonic locations in the same patient, the endoscopic Mayo score was evaluated based on the most severe lesion. In order to avoid any bias in endoscopic scoring, all colonoscopies were performed by the same endoscopist. All patients were prospectively followed for 12 months. Visits were scheduled at months 6 and 12. In addition, patients were instructed to come to the IBD Unit or to the Emergency Department any time outside the scheduled visits if needed. Clinical relapse was defined as the presence of rectal bleeding together with any of the following: the need for any remission induction treatment (including topical drugs); any treatment escalation (defined as the need for a dose increment, including topical medication, or any drug changes); and the need for hospitalization or colectomy.
Demographic and clinical parameters were compiled and summary statistics were calculated. The potential influences of gender, age, duration of the disease, smoking habits and extent of the disease according to the Montreal classification in relation to the different Mayo endoscopic subgroups were evaluated. Univariate analysis was performed with the χ 2 test and Fisher's exact test as appropriate. Multivariate analysis was done by unconditional logistic regression, in which clinical relapse was considered as the dependent variable and all the demographic, clinical and endoscopic data were considered as independent variables. The impact of the endoscopic Mayo score on the time to UC relapse was evaluated by Kaplan-Meier regression analysis. Statistical significance was accepted at p < 0.05. All statistical tests were performed with the SPSS 15.0 statistical software package (Chicago, IL).
Based on our previous experience in clinical practice, an endoscopic Mayo score of 0 was expected to be twice as frequent as a score of 1 in the study population (ratio score 0/score 1 of 2). With the hypothesis of a risk of relapse over the 1-year period of 5% in patients with endoscopic Mayo score of 0 and 20% in of those with a score of 1, a total of 180 patients should be included in the study for a type I error of α = 0.05 and a type II error of β = 20%.
Results
One hundred and eighty-seven consecutive UC patients with mucosal healing were finally included ( Figure 1 ) (94 men [50.3%], mean age 52 years). The demographic and clinical characteristics of the study population are shown in Table 1 . According to the Montreal classification, the largest number of patients belonged to the E2 group (42%). One hundred and twenty-six patients (67.3%) had an endoscopic Mayo score of 0 and 61 (32.7%) had a score of 1. Demographic and clinical characteristics were similar in the two groups ( Table 1) .
The treatment for UC at the time of inclusion in the study is shown in Table 2 . The most commonly used drugs were 5-aminosalicylates (76.2% in patients with Mayo score 0 and 77.1% in those with score 1). Immunosuppressive and anti-tumour necrosis factor (TNF) drugs were more frequently used at entry by patients with a Mayo score of 1, whereas the absence of any maintenance therapy was more frequently observed in patients with a Mayo score of 0 (p < 0.05) ( Table 2) .
A total of 36 (19.2%) patients had a clinical relapse of the disease over the first 6 months of follow-up. Relapses occurred more frequently in patients with a basal endoscopic Mayo score of 1 (22 patients, 36.1%) than in those with a Mayo score of 0 (14 patients, 11.1%) (p < 0.01). At the end of the study, the disease had relapsed in 49 patients (26.2%), 25 (41.0%) of those with an endoscopic Mayo score of 1 and 24 (19.3%) of those with a Mayo score of 0 (p < 0.01). The Kaplan-Meier survival analysis shown in Figure 2 shows the cumulative probability of freedom for relapse in patients with Mayo endoscopic scores of 0 and 1 for the 1-year study period. Log-rank test analysis detected significant differences between the two Mayo score groups (χ 2 = 13.46, p = 0.0002). The impact of the endoscopic Mayo score on the clinical relapse of UC was significant for all three extents of disease according to the Montreal classification (Figure 3) . Moreover, UC relapsed more frequently in patients with a Mayo score of 1 independently of smoking habit ( Figure 4) .
The need for drug increase over the first 6 months of follow-up is shown in Table 3 . Among patients requiring treatment escalation, the dose of 5-aminosalicylates was increased in most of them, and corticosteroids were also frequently needed. Treatment escalation, including the need for immunosuppressant and biological drugs, was more frequently required for patients with a basal endoscopic Mayo score of 1 than for those with a score of 0 (p < 0.05). None of the patients underwent colectomy during the follow-up.
An endoscopic Mayo score of 1 (odds ratio [OR] 6.41, 95% confidence interval [CI] 2.77-14.82, p < 0.0001) and E2 disease extent (OR 1.53, 95% CI 0.90-2.61, p = 0.10) were associated with clinical relapse during the first 6 months of follow-up in the univariate analysis. In the multivariate analysis, the only factor independently associated with UC relapse was an endoscopic Mayo score of 1 (OR 6.27, 95% CI 2.73-14.40, p < 0.001) ( Table 4 ).
Discussion
The present study demonstrates that patients with UC and an endoscopic Mayo score of 1 have a significantly higher relapse rate than those with a Mayo score of 0. Therefore, UC patients with Mayo scores of 0 and 1 are two different populations in terms of clinical course of the disease, and consideration of both endoscopic scores as mucosal healing in patients with UC should be revisited.
Mucosal healing has become an important aim in numerous studies and clinical trials, first in Crohn's disease and more recently in UC. 11, 12 Nevertheless, the definition and significance of mucosal healing in UC remain very variable. 13, 14 The results of this large prospective longitudinal study, which includes 187 consecutive patients with endoscopic Mayo scores 0 and 1 demonstrated that in clinical practice, outside the conditions of clinical trials, an endoscopic Mayo score of 1 is associated with a higher relapse rate compared with a score of 0. Starting from the time of surveillance colonoscopy, UC relapsed in 11.1% of patients with an endoscopic Mayo score of 0 compared with 36.6% of those with a score of 1 over a period of 6 months. Based on these results, we strongly support the concept of mucosal healing being defined as an endoscopic Mayo score of 0, thus excluding the Mayo score 1 from this concept. Very few studies have evaluated the prognostic value of mucosal healing in UC by comparing Mayo scores 0 and 1, and they have important limitations. 15, 16 Yokoyama et al. 15 reported on just 38 patients with Mayo scores from 0 to 3, who were followed up for 5 years. They found that none of the patients with a Mayo score of 0 relapsed over that time, whereas 7% of patients with a Mayo score of 1 did so. They concluded that only a Mayo score of 0 should be considered to represent mucosal healing, but the low numbers of patients and relapses made it difficult to draw any definite conclusion. Similar results were reported by Nakarai et al. 16 in a recent retrospective study, but the retrospective study design and the lack of information about the therapeutic impact of relapses in their study population limit the relevance of their report.
The main information on this topic has been obtained from subanalysis or post hoc analysis of clinical trials evaluating different drugs for UC and evaluating clinical remission and mucosal healing (Mayo scores of both 0 and 1) as outcome variables. These trials had the strengths of a very precise definition of relapse and a blind evaluation. On the other hand, they only evaluated a highly specific subgroup of patients with UC (e.g. severe disease in studies with anti-TNF drugs) 2, 17 and thus extrapolation of their results to clinical practice should be done cautiously. The Active Ulcerative Colitis Trial (ACT) 1 and 2 subanalyses presented very relevant data, in that colectomy rates were similar for both Mayo 0 and Mayo 1 groups. 2 Colectomy was not required in any of the patients included in our study, and thus our results cannot be considered to support these previous data. The differences between the two study populations are very noticeable. Our patients had clearly milder UC, and in such patients colectomies are less likely. Considering the results of these previous studies and the present one, some suggestions can be made. First, based on ACT 1 and 2 subanalyses for severe UC cases with a high probability of requiring colectomy, definition of mucosal healing as Mayo score 0 and 1 may be appropriate. However, a different endoscopic index, such as the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), developed after the inclusion period of our study started, could be preferred for patients with more severe UC. 18 In the ACT 1 and 2 subanalyses, no difference was observed between patients with Mayo scores of 0 and 1 in terms of symptomatic remission at weeks 30 or 54 or in corticosteroid-free symptomatic remission at these time points among infliximab-treated patients who achieved clinical remission at week 8.
2 Even more surprising is that the number of patients in corticosteroid-free remission tended to be higher in the Mayo score 1 group than in the Mayo score 0 group. 2 These results clearly differ from our study, in which the rate of patients in remission was higher in those with Mayo score 0 and the need for corticosteroid treatment was more common in patients with score 1. Once again, comparisons between the ACT 1 and 2 results and the present study cannot be made, since they included different study populations in terms of severity of the disease and the need for anti-TNF therapies. The same explanation can be applied to the absence of significant differences in rates of relapses (25% for Mayo score 0 and 30% for Mayo score 1) in a Japanese study of UC patients being treated with tacrolimus. 19 Nevertheless, the number of patients achieving mucosal healing in that study was very low, and thus its results should be analysed cautiously.
Opposite results to the present study were reported in an Italian study of patients with UC being treated with mesalazine. 20 They evaluated 56 patients with Mayo scores 0 and 1 and concluded that the risk of UC relapse was similar in the two groups. Contrarily to that study, we accurately evaluated the need for any therapeutic modification, including increasing the dose of the same drug or the need to add any topical treatment, as part of the definition of relapse. In addition, and according to the ECCO UC consensus, 21 in which 47/59 members considered rectal bleeding an essential component of relapse, rectal bleeding was used in our study to define relapse. Although most patients in the present study only needed to increase the dose of 5-aminosalicylates for relapse, the need for other drugs, such as corticosteroids, immunosuppressants or biological drugs, was significantly higher in the group with Mayo score 1, thus confirming the worst prognosis of these patients. Moreover, we minimized the bias in endoscopic scoring, since all explorations were performed by the same endoscopist, who is in addition an expert in IBDs and has extensive experience in performing colonoscopies in this specific group of patients. Actually, the interobserver agreement for endoscopic scoring in UC patients has been reported to be only fair to moderate. 22 In the present study, relapses in patients with an endoscopic Mayo score of 1 occurred more frequently over the first 6 months after colonoscopy, thus showing that the absence of complete mucosal healing is a short-term marker of an unfavourable clinical course in UC. The UC relapse rate observed in the present study for patients with Mayo score 0 was similar to that reported in previous studies including a lower number of patients. 23, 24 The present study included consecutive patients with UC and mucosal healing, independently of their basal treatment. Although this could be considered as a limitation of the study due to the limited number of patients with severe disease and requiring immunosuppressant and biological drugs, our patient population reflects clinical practice, far from the limitations of clinical trials. Limitations of the study are the absence of data on calprotectin in all patients and the fact that histological correlation was not evaluated. Another limitation of the study is that all patients were in remission at least 3 months before inclusion, but we had not calculated whether differences in time in remission at an earlier time before inclusion differed between the two groups. The endoscopist who performed all the colonoscopies specialized in IBD; this could be considered as a strength because of his greater experience with such patients, but in fact was a limitation because he was not blind to the medical history and the treatment of the patients at the time of colonoscopy. Basal treatment of both groups was quite similar because most patients had only needed 5-ASA, but patients with Mayo score 1 had previously required more immunosuppressive or biological drugs, so this could be considered as a bias because maybe those patients were from a subgroup with more severe UC. The large number of patients evaluated, the prospective and longitudinal design, the minimized bias at endoscopic scoring, and the close monitoring for therapeutic escalation requirements are strengths of the present study.
In conclusion, the present study demonstrated that patients with an endoscopic Mayo score of 1 have a higher risk of relapse and require treatment escalation more often than patients with a Mayo score of 0. Mucosal healing should therefore be considered only for patients with an endoscopic Mayo score of 0, and complete mucosal healing should be the therapeutic goal in UC patients.
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